... and here you have HCQ - also on nih.gov
"We do not believe that randomized controlled studies are necessary before HCQ is authorized for general use because the efficacy seen in studies already performed indicates that control patients in such studies might die unnecessarily, and because the time delay to perform any such study would cause yet more deaths by preventing HCQ use when it is most needed: immediately! Our study has shown that good evidence of efficacy exists and that there is no safety, cost or supply reason to not treat now. Unnecessary death from delayed treatment is too high a price to pay for greater certainty of knowledge. Many may have already died unnecessarily as a result of inaccurate HCQ information. It is imperative that we do not further add to the COVID-19 death toll by refusing to prescribe HCQ."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534595/
Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies. We hypothesized that a systematic review would show HCQ to be effective against COVID-19, more effective when provided earlier, not associated ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534595/
Scroll down on this page and you have Ivermectin on the list. This is a page on nih.gov
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/
Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19 | COVID-19 Treatment Guidelines
Review this table to learn about the characteristics of drugs under study for the treatment of COVID-19.
https://www.covid19treatmentguidelines.nih.gov/tables/table-2e/
